Treatment Research Initiative to Cure ALS
Nevrargenics participates in the first TRICALS workshop at Schiphol, Netherlands, on ALS since the COVID pandemic.
Nevrargenics participates in the first TRICALS workshop at Schiphol, Netherlands, on ALS since the COVID pandemic.
Nevrargenics launches efficacy studies on MS and ALS models through Experimentica and Charles River respectively.
CEO Andy Whiting gives an interview to Liza Laws, Senior Editor of Labiotech about neurodegeneration and Nevrargenics's drugs.
Research collaboration launch with Professor Susan Duty at King’s College, looking the application of our drugs in Parkinson’s disease models.
Nevrargenics acquires its own premises for the development of its offices and laboratories on Mandale Park in Durham.
Two (once weekly and twice weekly dosing), 28 day tox studies were completed on NVG0645 showing a potential therapeutic window.
Nevrargenics reports that lead drug candidate provides neuroprotection in a 6-hydroxydopamine model of Parkinson’s disease.
Nevrargenics reports multi-neuro-restorative and protective effects using lead drug as a new therapeutic strategy for ALS.
